GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kangji Medical Holdings Ltd (HKSE:09997) » Definitions » Debt-to-EBITDA

Kangji Medical Holdings (HKSE:09997) Debt-to-EBITDA : 0.07 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Kangji Medical Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kangji Medical Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$7 Mil. Kangji Medical Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$41 Mil. Kangji Medical Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$734 Mil. Kangji Medical Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.07.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Kangji Medical Holdings's Debt-to-EBITDA or its related term are showing as below:

HKSE:09997' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01   Med: 0.04   Max: 0.08
Current: 0.07

During the past 7 years, the highest Debt-to-EBITDA Ratio of Kangji Medical Holdings was 0.08. The lowest was 0.01. And the median was 0.04.

HKSE:09997's Debt-to-EBITDA is ranked better than
89.81% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs HKSE:09997: 0.07

Kangji Medical Holdings Debt-to-EBITDA Historical Data

The historical data trend for Kangji Medical Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kangji Medical Holdings Debt-to-EBITDA Chart

Kangji Medical Holdings Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial - 0.02 0.01 0.08 0.07

Kangji Medical Holdings Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.12 0.06 0.08 0.07

Competitive Comparison of Kangji Medical Holdings's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Kangji Medical Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kangji Medical Holdings's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kangji Medical Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kangji Medical Holdings's Debt-to-EBITDA falls into.



Kangji Medical Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kangji Medical Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.68 + 41.436) / 682.498
=0.07

Kangji Medical Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.68 + 41.436) / 733.622
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Kangji Medical Holdings  (HKSE:09997) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Kangji Medical Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kangji Medical Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Kangji Medical Holdings (HKSE:09997) Business Description

Traded in Other Exchanges
Address
No. 1668 Chunjiang East Road, Tonglu Economic Development Zone, Zhejiang Province, Hangzhou, CHN
Kangji Medical Holdings Ltd is engaged in the production and sales of minimally invasive surgical instruments and accessories. The company offers a product portfolio to provide physicians and hospitals with one-shop and tailored surgical solutions for four surgical specialties OBGYN, general surgery, urology, and thoracic surgery. It manufactures and sells both disposable and reusable products. Its product portfolio includes disposable trocars, polymer ligation clips, disposable electrocoagulation forceps, and reusable trocar and forceps. It derives the majority of its revenue from Mainland China.
Executives
Butterfield Trust (asia) Limited 2301 Trustee
Fortune Spring Zm Aa Limited 2101 Beneficial owner
Yg Aa Limited 2201 Interest of corporation controlled by you
Bos Trustee Limited 2201 Interest of corporation controlled by you
Zhong Ming 2501 Other
Fortune Spring Yg B Limited 2101 Beneficial owner
Shentu Yinguang 2501 Other
Fortune Spring Zm B Limited 2101 Beneficial owner
Credit Suisse Trust Limited 2201 Interest of corporation controlled by you
Bonderman David 2201 Interest of corporation controlled by you
Coulter James George 2201 Interest of corporation controlled by you
Keyhole Holding Limited 2101 Beneficial owner
Tpg Asia Genpar Vii Advisors, Inc. 2201 Interest of corporation controlled by you
Tpg Asia Genpar Vii, L.p. 2201 Interest of corporation controlled by you
Tpg Group Holdings (sbs) Advisors, Inc. 2201 Interest of corporation controlled by you

Kangji Medical Holdings (HKSE:09997) Headlines

No Headlines